Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria
Clinical & Experimental Allergy · 2023
DOI: 10.1111/cea.14402 ↗At a glance
Journal article in Clinical & Experimental Allergy, 2023. Written by Katrine Baumann and 9 co-authors. Institution: Urticaria Center of Reference and Excellence (UCARE), Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denm…. Major MEDLINE topics: Chronic Urticaria, Anti-Allergic Agents, Urticaria. Cited 11 times so far (Crossref); 9 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Novo Nordisk Fonden.
Abstract (original language)
Intet abstract tilgængeligt.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Urticaria Center of Reference and Excellence (UCARE), Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark.
- RefLab ApS, Copenhagen, Denmark.
- LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
- Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark.
- Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
ORCID profiles: Katrine Baumann, Ditte Georgina Zhang, Misbah Noshela Ghazanfar, Marcus Maurer
Funding
- Novo Nordisk Fonden
Cite
APA
Baumann, K., Jørgensen, A. R., Sørensen, J. A., Zhang, D. G., Ghazanfar, M. N., Skov, P. S., Woetmann, A., Vestergaard, C., Maurer, M., & Thomsen, S. F. (2023). Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14402
Vancouver
Baumann K, Jørgensen AR, Sørensen JA, Zhang DG, Ghazanfar MN, Skov PS, et al. Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. 2023. doi:10.1111/cea.14402
BibTeX
@article{Baumann2023,
author = {Baumann, Katrine and Jørgensen, Astrid-Helene Ravn and Sørensen, Jennifer Astrup and Zhang, Ditte Georgina and Ghazanfar, Misbah Noshela and Skov, Per Stahl and Woetmann, Anders and Vestergaard, Christian and Maurer, Marcus and Thomsen, Simon Francis},
title = {Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria},
journal = {Clinical & Experimental Allergy},
year = {2023},
doi = {10.1111/cea.14402}
}
EUVIMED